Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
viernes, 13 de febrero de 2026
Gene therapy startups push past old limits to reach more patients With gene therapy now a clinical reality, innovators are designing delivery systems that can sustain lifelong correction, handle complex genes, and make treatments accessible to more patients. +++++
https://www.drugdiscoverynews.com/gene-therapy-startups-push-past-old-limits-to-reach-more-patients-17003
In 2026, drug discovery faces a higher bar
Biopharma’s recovery is real, but the data show a sector that now rewards validated biology, late-stage execution, and commercial relevance.
https://www.drugdiscoverynews.com/in-2026-drug-discovery-faces-a-higher-bar-16997
A faster route to active GPCRs
GPCRs drive a huge portion of today’s drug market, but producing them in a functional form remains a major bottleneck for discovery and structural studies.
https://www.drugdiscoverynews.com/a-faster-route-to-active-gpcrs-16977
Exploring the tiny robots improving drug delivery from inside the body
Moved by magnets or ultrasound waves, these tiny robots make delivering drugs more accurate and effective.
https://www.drugdiscoverynews.com/exploring-the-tiny-robots-improving-drug-delivery-from-inside-the-body-16998
Sustained-release drug delivery targets pediatric inherited retinal disease
PolyActiva and RareSight are pairing pro-drug chemistry with targeted ocular delivery to address early-stage barriers in rare pediatric retinal disorders.
https://www.drugdiscoverynews.com/sustained-release-drug-delivery-targets-pediatric-inherited-retinal-disease-16945
No hay comentarios:
Publicar un comentario